SCHEMBL4053408

SCHEMBL4053408

Cc1cccc(-c2nc3ccc(-c4ccccc4C(F)(F)F)cc3o2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 8/20 0.51
RAB9A P51151 8/20 0.51
SMN1; SMN2 Q16637 5/20 0.51
KDM4E B2RXH2 5/20 0.51
HPGD P15428 4/20 0.51
ALDH1A1 P00352 4/20 0.51
MAPT P10636 4/20 0.51
GPR119 Q8TDV5 1/20 0.48
VSIR Q9H7M9 3/20 0.48
TRPA1 O75762 1/20 0.46
HSD17B10 Q99714 2/20 0.45
PDCD1 Q15116 1/20 0.45
CD274 Q9NZQ7 1/20 0.45
BACE1 P56817 1/20 0.45
TP53 P04637 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4058082 0.88 BACE1 (0.51) NPC1RAB9ASMN1; SMN2KDM4EHPGD
SCHEMBL4057762 0.87 BACE1 (0.46) KDM4EMAPTVSIRTRPA1PDCD1
SCHEMBL4051587 0.87 VSIR (0.51) NPC1RAB9AKDM4EHPGDALDH1A1
SCHEMBL4051500 0.85 NPC1 (0.54) NPC1RAB9ASMN1; SMN2KDM4EHPGD
SCHEMBL4058059 0.84 VSIR (0.61) NPC1RAB9ASMN1; SMN2KDM4EHPGD
SCHEMBL4054585 0.83 GPR119 (0.50) GPR119VSIRTRPA1PDCD1CD274
SCHEMBL4059846 0.83 P2RY14 (0.47) NPC1RAB9ASMN1; SMN2MAPTGPR119
SCHEMBL4059707 0.82 NPC1 (0.62) NPC1RAB9ASMN1; SMN2KDM4EHPGD
SCHEMBL4053451 0.81 NPC1 (0.52) NPC1RAB9ASMN1; SMN2KDM4EALDH1A1
SCHEMBL5540262 0.79 SCN9A (0.53) TRPA1BACE1HSD11B1SCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-20050101647-A1 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-12 US disclosed
EP-1460067-A1 BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Chemical Industries, Ltd. (JP) 2004-09-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101647-A1 Bicyclic derivative, its production and use ABL1, SRC, PTK2B NPC1 4740/4885RAB9A 1184/4885SMN1; SMN2 4289/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.